Sunovion

About: Sunovion is a company organization based out in London, United Kingdom. It is known for research contribution in the topics: Lurasidone & Placebo. The organization has 572 authors who have published 1022 publications receiving 18488 citations. The organization is also known as: Sunovion Pharmaceuticals, Inc..

Use of B-2 bronchodilator drugs

Abstract: Improved use of selective β 2 sympathomimetic bronchodilator drugs in the therapy of obstructive or inflammatory airways disease, e.g. asthma, comprises use in enantiomeric rather than conventional racemic form. The improved use reduces occurrence of side effect, e.g. exacerbation of basal disease status or compromise or deterioration of lung function.

Methods for treating allergic disorders using norastemizole

Abstract: Methods and compositions are disclosed utilizing metabolic derivatives of astemizole for the treatment of allergic disorders while avoiding the concomitant liability of adverse effects associated with the astemizole The metabolic derivatives of astemizole are also useful for the treatment of retinopathy and other small vessel disorders associated with diabetes mellitus and such other conditions as may be related to the antihistamine activity of astemizole For example, the metabolic derivatives of astemizole are useful for the treatment of asthma, motion sickness, and vertigo, without the concomitant liability of adverse effects associated with astemizole Furthermore, the metabolic derivatives of astemizole, in combination with non-steroidal anti-inflammatory agents or other non-narcotic analgesics, or in combination with a decongestant, cough suppressant/antitussive or expectorant, are useful for the treatment of cough, cold, cold-like, and/or flu symptoms and the discomfort, headache, pain, fever, and general malaise associated therewith, without the concomitant liability of adverse effects associated with astemizole

Changes in Quality of Life (QoL) and Depressive Symptoms in a Long-term Open-label Extension (OLE) of Eslicarbazepine Acetate (ESL) Monotherapy Studies in Adults with Refractory Partial-onset Seizures (POS) (P1.234)

Abstract: OBJECTIVE: To evaluate changes in Quality of Life in Epilepsy-31 (QOLIE-31) and Montgomery- Asberg Depression Rating Scale (MADRS) scores during the first 12 months of an ESL monotherapy extension period. BACKGROUND: Two 18-week double-blind studies demonstrated that ESL monotherapy is effective in patients with POS not well controlled by 1-2 antiepileptic drugs (AEDs). ESL is not approved for use as monotherapy. In the OLE study (093-050), 57[percnt] remained on ESL monotherapy (mean 1609 mg QD); improvements in seizure control were maintained. We have analyzed QoL and depressive symptoms during the OLE phase. DESIGN/METHODS: Patients who received 蠅3 weeks of double-blind ESL (1200/1600mg QD) were eligible for the OLE (ESL 800-2400mg QD, plus 1 or 2 additional AEDs). QOLIE-31 and MADRS scores were assessed for the ITT population after 6 and 12 months of OL treatment (at 03/21/2014), using descriptive statistics. RESULTS: A total of 274 patients entered the OLE (median age 37 years; 84[percnt] Caucasian; 36[percnt] had epilepsy for 蠅20 years; 70[percnt] and 30[percnt] had been taking 1 and 2 AEDs, respectively). QOLIE-31 overall scores increased between baseline (59.3±16.6; mean±SD [n=259]) and the 6-month and 12-month visits (64.5±16.8 [n=223]; 67.1±16.3 [n=166]). QOLIE-31 subscale scores increased slightly. Mean MADRS total score was 6.9±6.8 at baseline (n=274), versus 5.3±6 after six months (n=234), and 4.9±6.1 after 12 months (n=178). MADRS subscale scores were unchanged or slightly decreased. Among patients who discontinued early (n=78), mean QOLIE-31 score declined by 2.5 points, and mean MADRS score increased by 2.2 points between baseline and discontinuation/end of study. CONCLUSIONS: In patients with POS, improvements in QoL (QOLIE-31) and depressive symptoms (MADRS) in double-blind ESL monotherapy studies were maintained/increased in patients who completed 12 months of OL treatment. Improvements in QOLIE-31 score met the criterion for a minimally clinically important difference (蠅 5 points). Disclosure: Dr. Gilliam has nothing to disclose. Dr. Cheng has received personal compensation for activities with Sunovian Pharmaceuticals, Inc. Dr. Blum has received personal compensation for activities with Sunovion Pharmaceuticals Inc. as an employee.